The Taste of Tomorrow: Genetic Engineering – The Daily Progress
By Dr. Matthew Watson
The Taste of Tomorrow: Genetic Engineering The Daily Progress Mr. Schonwald spent a considerable amount of time researching how genetic engineering might impact the salad bar of 2035. He explained, “When I started this project, I had a healthy suspicion of [genetically modified organisms]. I thought the idea of ... |
Uncategorized
Comments Off on The Taste of Tomorrow: Genetic Engineering – The Daily Progress |
July 21st, 2013
Grist Challenges Its Own Shaky Crop Biotechnology Reporting, Sets Stage For … – Forbes
By Dr. Matthew Watson
Grist Challenges Its Own Shaky Crop Biotechnology Reporting, Sets Stage For ... Forbes That's been the reality for years at the otherwise respectable environmental news site Grist on the issue of agricultural biotechnology. This is why the current series by food writer Nathaniel Johnson reassessing Grist's own reporting on crop ... |
Uncategorized
Comments Off on Grist Challenges Its Own Shaky Crop Biotechnology Reporting, Sets Stage For … – Forbes |
July 21st, 2013
Commit To Purchase Puma Biotechnology At $45, Earn 14.8% Annualized – Forbes
By Dr. Matthew Watson
Commit To Purchase Puma Biotechnology At $45, Earn 14.8% Annualized Forbes Investors considering a purchase of Puma Biotechnology Puma Biotechnology, Inc. (NYSE: PBYI) shares, but cautious about paying the going market price of $53.61/share, might benefit from considering selling puts among the alternative strategies at their ... |
Uncategorized
Comments Off on Commit To Purchase Puma Biotechnology At $45, Earn 14.8% Annualized – Forbes |
July 21st, 2013
Biotechnology – Revolutions with Jon Faine – ABC Local
By Dr. Matthew Watson
 ABC Local | Biotechnology - Revolutions with Jon Faine ABC Local This week Revolutions looks at the new possibilities opened up by biotechnology and talks to listeners about the procedures they've had, procedures that would have been thought impossible just a few decades ago. Joining Jon Faine for the discussion is ... |
Uncategorized
Comments Off on Biotechnology – Revolutions with Jon Faine – ABC Local |
July 21st, 2013
The real impact for healthcare and biotechnology of the Supreme Court’s … – Lexology (registration)
By Dr. Matthew Watson
The real impact for healthcare and biotechnology of the Supreme Court's ... Lexology (registration) On June 13, 2013, the Supreme Court issued a decision supposedly resolving the patentability of DNA in Association for Molecular Pathology v. Myriad Genetics. Immediately, all parties on both sides of the case declared victory. The American Civil ... |
Uncategorized
Comments Off on The real impact for healthcare and biotechnology of the Supreme Court’s … – Lexology (registration) |
July 21st, 2013
The top biotechnology companies in the Puget Sound area (slide show) – Puget Sound Business Journal (Seattle) (blog)
By Dr. Matthew Watson
The top biotechnology companies in the Puget Sound area (slide show) Puget Sound Business Journal (Seattle) (blog) The region's top biotechnology companies are extremely secretive about their revenues. That's one conclusion that can be drawn from the Puget Sound Business Journal's list of the top biotech firms in the area. Eleven of the top 25 companies would not ... |
Uncategorized
Comments Off on The top biotechnology companies in the Puget Sound area (slide show) – Puget Sound Business Journal (Seattle) (blog) |
July 21st, 2013
Biotechnology: Monsanto drops new European GM food plans – Presseurop (English)
By Dr. Matthew Watson
 Los Angeles Times | Biotechnology: Monsanto drops new European GM food plans Presseurop (English) United States biotech giant Monsanto is ending all but one project to grow GM foods in Europe, reports German daily Die Welt. The firm announced on July 17 that it is withdrawing all permits requested to the European Commission to grow genetically ... In Perspective: Anti-GM vitriol risesagprofessional.com Monsanto drops GM crop plan in EUBBC News Millions Against Monsanto: On the Road to VictoryTruth-Out The Southern Times -Malaysia Sun all 82 news articles » |
Uncategorized
Comments Off on Biotechnology: Monsanto drops new European GM food plans – Presseurop (English) |
July 21st, 2013
Applause for business achievements – Lima Ohio
By Dr. Matthew Watson
Applause for business achievements Lima Ohio He is a 1995 graduate of The Ohio State University with a bachelor's degree in science in molecular genetics. He then attended Kirksville College of Osteopathic Medicine in Kirksville, Mo., where he received his Doctorate of Osteopathic Medicine. In ... |
Uncategorized
Comments Off on Applause for business achievements – Lima Ohio |
July 21st, 2013
Treat an upset tummy with curd – Times of India
By Dr. Matthew Watson
Treat an upset tummy with curd Times of India Manuela Raffatellu, assistant professor of microbiology and molecular genetics, and colleagues at UC Irvine and the University of Washington identified how a probiotic strain of E. coli reduces salmonella colonization by competing with this pathogen ... |
Uncategorized
Comments Off on Treat an upset tummy with curd – Times of India |
July 21st, 2013
CAMH scientists discover genetic changes that may contribute to the onset of … – Placentia Charter
By Dr. Matthew Watson
 Placentia Charter | CAMH scientists discover genetic changes that may contribute to the onset of ... Placentia Charter The study is published in the current issue of Human Molecular Genetics, and was funded by the Canadian Institutes of Health Research (CIHR). In the first study of its kind, scientists at CAMH and The Centre for Applied Genomics (TCAG) at The Hospital ... |
Uncategorized
Comments Off on CAMH scientists discover genetic changes that may contribute to the onset of … – Placentia Charter |
July 21st, 2013
“Molecular Postal System” Used in Quest to Develop Low-Cost Sterilization … – HealthCanal.com
By Dr. Matthew Watson
“Molecular Postal System” Used in Quest to Develop Low-Cost Sterilization ... HealthCanal.com WINSTON-SALEM, N.C. - As an expert in molecular genetics, Colin E. Bishop, Ph.D.'s, usual role at the Wake Forest Baptist Medical Center's Institute for Regenerative Medicine is to apply the techniques of genetics and developmental biology to the ... |
Uncategorized
Comments Off on “Molecular Postal System” Used in Quest to Develop Low-Cost Sterilization … – HealthCanal.com |
July 21st, 2013
Doctors apply lessons from boy’s case in sequencing genes of 25 other patients – Milwaukee Journal Sentinel
By Dr. Matthew Watson
Doctors apply lessons from boy's case in sequencing genes of 25 other patients Milwaukee Journal Sentinel Writing with two dozen colleagues, Howard Jacob, head of human and molecular genetics at the Medical College of Wisconsin, says the use of sequencing in hospitals "may still be debated, but we challenge the fence sitters to do 20 cases of their own and ... |
Uncategorized
Comments Off on Doctors apply lessons from boy’s case in sequencing genes of 25 other patients – Milwaukee Journal Sentinel |
July 21st, 2013
DNA enzyme’s speed confirms physics law – Futurity: Research News
By Dr. Matthew Watson
DNA enzyme's speed confirms physics law Futurity: Research News “Ever since the original experiments, we've noticed RecBCD molecules have quite a broad range of speeds,” says Kowalczykowski, a member of the department of microbiology and molecular genetics and the UC Davis Cancer Center. Liu used the ... |
Uncategorized
Comments Off on DNA enzyme’s speed confirms physics law – Futurity: Research News |
July 21st, 2013
LIVE Twitter Chat Featuring Next-Generation Sequencing Expert from The … – PR Web (press release)
By Dr. Matthew Watson
LIVE Twitter Chat Featuring Next-Generation Sequencing Expert from The ... PR Web (press release) Dr. Santani holds specialty board certifications in Clinical Molecular Genetics and Clinical Cytogenetics. Her primary focus is on new test development and adoption of next generation sequencing technologies for diagnostic testing. Dr. Santani has ... |
Uncategorized
Comments Off on LIVE Twitter Chat Featuring Next-Generation Sequencing Expert from The … – PR Web (press release) |
July 21st, 2013
Paying for Human Eggs, Ivan Illich and Jerry Brown
By Dr. Matthew Watson
California's pay-for-eggs bill is
stalled in a technical parliamentary process as opponents continue to
wage their campaign urging Gov. Jerry Brown to veto the proposal,
which swept easily through the legislature.
stalled in a technical parliamentary process as opponents continue to
wage their campaign urging Gov. Jerry Brown to veto the proposal,
which swept easily through the legislature.
The latest volley against the
industry-sponsored measure appeared this week as an op-ed in The Sacramento Bee. The legislation would allow women to be paid for eggs for scientific research. The op-ed piece invoked the philosopher Ivan Illich, a
longtime friend of Jerry Brown and much respected by him.
industry-sponsored measure appeared this week as an op-ed in The Sacramento Bee. The legislation would allow women to be paid for eggs for scientific research. The op-ed piece invoked the philosopher Ivan Illich, a
longtime friend of Jerry Brown and much respected by him.
Written by Diane Tober and Nancy
Scheper-Hughes of the Center for Genetics and Society of Berkeley,
the July 16 article said,
Scheper-Hughes of the Center for Genetics and Society of Berkeley,
the July 16 article said,
“The late historian of science and
technology, Ivan Illich, warned against the processes of medical
industries which 'create new needs and control their satisfaction and
turn human beings and their creativity into objects.'"
The op-ed said,
“Women's research eggs (have) become
the hot new bio-product, increasing the profits of the
multibillion-dollar-per-year infertility industry at the expense of
women's health, safety and possibly, their future fertility. Is this
the 'equity' we want for ourselves, our sisters and our daughters?”
In 2003, Brown wrote a remembrance of
Illich, whom he first met in 1976. Brown said that Illich
Illich, whom he first met in 1976. Brown said that Illich
“...bore witness to the destructive
power of modern institutions that 'create needs faster than they can
create satisfaction, and in the process of trying to meet the needs
they generate, they consume the earth.'”
The egg compensation bill (AB926 by
Assemblywoman Susan Bonilla, D-Concord) would remove a ban in
California on paying women who provide their eggs for scientific
research. Currently women who provide eggs for fertility purposes can
be paid, sometimes as much as $50,000, depending on the
characteristics of the woman providing the eggs. The bill would not
alter the ban on using research funds from the California stem cell
agency to pay for eggs. However, the agency next week will consider a proposal to allow use of agency funds to purchase stem cell lines
derived from eggs through compensation. (For
more information on
the bill,
see here, here and here.)
Assemblywoman Susan Bonilla, D-Concord) would remove a ban in
California on paying women who provide their eggs for scientific
research. Currently women who provide eggs for fertility purposes can
be paid, sometimes as much as $50,000, depending on the
characteristics of the woman providing the eggs. The bill would not
alter the ban on using research funds from the California stem cell
agency to pay for eggs. However, the agency next week will consider a proposal to allow use of agency funds to purchase stem cell lines
derived from eggs through compensation. (For
more information on
the bill,
see here, here and here.)
The egg bill received final legislative
approval on July 1. The governor has 12 days to act on the measure
once it actually reaches his desk. However, as of this morning, the
legislation remained in what is known as the “engrossing and
enrolling” process. It could be a routine delay but the process can
also be used to manage the flow of legislation to the governor. Brown
is currently on a two-week trip to Germany and Ireland and is not
expected to return until near the first of August.
approval on July 1. The governor has 12 days to act on the measure
once it actually reaches his desk. However, as of this morning, the
legislation remained in what is known as the “engrossing and
enrolling” process. It could be a routine delay but the process can
also be used to manage the flow of legislation to the governor. Brown
is currently on a two-week trip to Germany and Ireland and is not
expected to return until near the first of August.
Source:Stem Cell Therapy
Comments Off on Paying for Human Eggs, Ivan Illich and Jerry Brown |
July 21st, 2013
California Stem Cell Agency to Commit 20 Percent of Remaining Cash
By Dr. Matthew Watson
The California stem cell agency next
Thursday is expected to move forward with plans to give away $128
million, roughly 20 percent of its remaining funds.
Thursday is expected to move forward with plans to give away $128
million, roughly 20 percent of its remaining funds.
The programs include the $70 million Alpha clinic plan, an ambitious five-year project that would be one
of the $3 billion agency's hallmark efforts. The other “concept”
rounds up next week include a $35 million “tools and technology”RFA and $23 million to recruit four more star, stem cell scientists to California.
of the $3 billion agency's hallmark efforts. The other “concept”
rounds up next week include a $35 million “tools and technology”RFA and $23 million to recruit four more star, stem cell scientists to California.
The agency has committed about $1.8
billion of its $3 billion so far with about $700 million available
for future spending. The remainder is going for the agency's
administrative expenses. Cash for new grants is expected to run out
sometime in 2017. Total cost of the agency's efforts run to about $6
billion because it operates with money borrowed by the state and must
pay interest.
billion of its $3 billion so far with about $700 million available
for future spending. The remainder is going for the agency's
administrative expenses. Cash for new grants is expected to run out
sometime in 2017. Total cost of the agency's efforts run to about $6
billion because it operates with money borrowed by the state and must
pay interest.
The agency is currently engaged in
developing a plan to develop new sources of funding with an eye on
some sort of public-private model. It solicited proposals in May for
help with the effort, with the goal of completing a plan by this
fall. At last report, however, the contract with the consultant had
not been let.
developing a plan to develop new sources of funding with an eye on
some sort of public-private model. It solicited proposals in May for
help with the effort, with the goal of completing a plan by this
fall. At last report, however, the contract with the consultant had
not been let.
The “strategic roadmap,” as it is
called, is likely to come up at next week's governing board meeting
along with a review of agency goals for the 2013-14 fiscal year.
called, is likely to come up at next week's governing board meeting
along with a review of agency goals for the 2013-14 fiscal year.
On the agenda is a proposal to modify the agency's ban on use of its funds to purchase stem cell lines derived from human eggs supplied by women who have been paid. That proposal will
also be heard by the agency's standards group next Wednesday.
also be heard by the agency's standards group next Wednesday.
The agency has additionally been busy
implementing recommendations from a performance audit in May 2012.
The audit said the agency was laboring under a range of problems that
include protection of its intellectual property and management of its
nearly 500 grants plus an inadequate ability to track its own
performance. A staff Power Point presentation seems to indicate that it is making substantial progress in solving the problems identified by the audit.
implementing recommendations from a performance audit in May 2012.
The audit said the agency was laboring under a range of problems that
include protection of its intellectual property and management of its
nearly 500 grants plus an inadequate ability to track its own
performance. A staff Power Point presentation seems to indicate that it is making substantial progress in solving the problems identified by the audit.
Next week's meeting will be in
Burlingame near the San Francisco Airport. Two remote locations where
the public can participate are also available in Los Angeles.
Addresses can be found on the agenda.
Burlingame near the San Francisco Airport. Two remote locations where
the public can participate are also available in Los Angeles.
Addresses can be found on the agenda.
The California Stem Cell Report will
provide live coverage of the meeting based on the Internet audiocast
with stories filed as warranted.
provide live coverage of the meeting based on the Internet audiocast
with stories filed as warranted.
Source:Stem Cell Therapy
Comments Off on California Stem Cell Agency to Commit 20 Percent of Remaining Cash |
July 21st, 2013
California’s $70 Million ‘Alpha’ Stem Cell Clinic Plan Headed for Approval Next Week
By Dr. Matthew Watson
 |
| Alpha clinic organizational diagram Graphic by CIRM |
California's stem cell agency next week
is likely to approve a $70 million plan to build a taxpayer-financed
chain of “Alpha” stem cell clinics in what could be a major step
towards making California the stem cell capital of the world,
is likely to approve a $70 million plan to build a taxpayer-financed
chain of “Alpha” stem cell clinics in what could be a major step
towards making California the stem cell capital of the world,
The proposal would create five centers
at existing institutions or businesses to be funded at up to $11
million each over five years. Also proposed is a coordination and
information center that would receive $15 million over five years.
at existing institutions or businesses to be funded at up to $11
million each over five years. Also proposed is a coordination and
information center that would receive $15 million over five years.
A story in Nature Medicine said that
the Alpha clinics would be the first-ever “clinical trials network focused around a broad therapeutic platform.”
the Alpha clinics would be the first-ever “clinical trials network focused around a broad therapeutic platform.”
The clinics are expected to draw stem
cell projects from the around the world as well as those
funded by the $3 billion California stem cell agency. The proposal
would be one of the largest single research efforts funded by the
agency, formally known as the California Institute for Regenerative
Medicine (CIRM) and use about 10 percent of its remaining cash.
cell projects from the around the world as well as those
funded by the $3 billion California stem cell agency. The proposal
would be one of the largest single research efforts funded by the
agency, formally known as the California Institute for Regenerative
Medicine (CIRM) and use about 10 percent of its remaining cash.
The Alpha clinics are aimed at creation
of a sturdy foundation for the stem cell industry in California,
capitalizing on the burgeoning, international lure of stem cell
treatments. Indeed, one of the objectives of the information center
is to divert people from dubious treatments elsewhere.
of a sturdy foundation for the stem cell industry in California,
capitalizing on the burgeoning, international lure of stem cell
treatments. Indeed, one of the objectives of the information center
is to divert people from dubious treatments elsewhere.
The plan would fill a “profound gap”
in quality information about stem cell treatments, according to a CIRM document, which said,
in quality information about stem cell treatments, according to a CIRM document, which said,
“By providing this resource, the public and potential patients
would be better educated and informed, whether or not they should opt
to enroll in clinical trials or approved treatments at any of the
Alpha clinics.”
The Alpha concept was first broached two years ago publicly by
CIRM President Alan Trounson, a pioneer in IVF research and the IVF
business. His proposal has received early and heavy
attention on the CIRM website with a video, blog items and a white paper.
CIRM President Alan Trounson, a pioneer in IVF research and the IVF
business. His proposal has received early and heavy
attention on the CIRM website with a video, blog items and a white paper.
The plan has received little critical
attention although a researcher from an institution that could be a
candidate for an Alpha clinic commented harshly in May on the California
Stem Cell Report, calling the proposal “an irresponsible waste”and a “boondoggle for some medical schools.” The researcher, who
asked that he/she not be identified, said,
attention although a researcher from an institution that could be a
candidate for an Alpha clinic commented harshly in May on the California
Stem Cell Report, calling the proposal “an irresponsible waste”and a “boondoggle for some medical schools.” The researcher, who
asked that he/she not be identified, said,
“CIRM will pay for an unneeded
infrastructure that will be empty space and staff sitting on their
hands 99 percent of the time. Or worse yet, CIRM will pay but
the space will be used for other things, other clinic procedures paid
for by insurance.”
Elie Dolgin's July 8 piece in Nature
Medicine quoted Mahendra Rao, director of the Center for Regenerative
Medicine at the US National Institutes of Health (NIH), as applauding the concept. However, Rao said he doesn't
anticipate the approach being tried nationally soon.
Medicine quoted Mahendra Rao, director of the Center for Regenerative
Medicine at the US National Institutes of Health (NIH), as applauding the concept. However, Rao said he doesn't
anticipate the approach being tried nationally soon.
Dolgin wrote,
“Rao regularly asks researchers
hoping to advance promising stem cell therapies whether they require
additional clinical infrastructure. 'So far, what they've told us is
they'll let us know if they need anything more than (the) programs
that we have already established,' he says.”
The question of the size of the demand
for Alpha clinics is not addressed in the CIRM concept plan. Also
absent is much discussion of the business aspects of the proposal. It
does mention “corporate sponsors” in passing. In a CIRM blog item
yesterday, Natalie DeWitt, special project director at the agency,
touched on business elements, declaring,
for Alpha clinics is not addressed in the CIRM concept plan. Also
absent is much discussion of the business aspects of the proposal. It
does mention “corporate sponsors” in passing. In a CIRM blog item
yesterday, Natalie DeWitt, special project director at the agency,
touched on business elements, declaring,
“(The proprosal) will yield better
clinical trial design, accelerated approval of high quality
treatments, and data and know-how to inform regulatory and
reimbursement decisions.”
Reimbursement is the industry euphemism
for creating ways to generate profits for stem cell firms.
for creating ways to generate profits for stem cell firms.
The proposal said applicants would have
to bring substantial support from their own institutions and
“demonstrate the potential to bring in a pipeline of additional
stem cell-based therapeutic trials as well as future funding streams
to sustain the clinic.” Applicants would also be “evaluated in
their ability to create a positive 'brand' that would attract
clinical trials.”
to bring substantial support from their own institutions and
“demonstrate the potential to bring in a pipeline of additional
stem cell-based therapeutic trials as well as future funding streams
to sustain the clinic.” Applicants would also be “evaluated in
their ability to create a positive 'brand' that would attract
clinical trials.”
Also up in the air was whether grant
reviewers, all of whom come from out-of-state, would have special
expertise to evaluate the business aspects of each applicant's
proposal along with their business track record.
reviewers, all of whom come from out-of-state, would have special
expertise to evaluate the business aspects of each applicant's
proposal along with their business track record.
What is before the CIRM directors July
25 at their meeting in Burlingame, Ca., is a request for approval of the concept, which
would be fleshed out for the RFA. The governing board almost always
approves staff concepts, although they may modify them slightly. A
number of directors come from institutions that are likely to be
applicants in the program. They can participate in voting on the
concept plan but would be barred from voting on any applications that
come in later. The two RFAs could go out as early as October with
approval of funding of applications one year from now.
25 at their meeting in Burlingame, Ca., is a request for approval of the concept, which
would be fleshed out for the RFA. The governing board almost always
approves staff concepts, although they may modify them slightly. A
number of directors come from institutions that are likely to be
applicants in the program. They can participate in voting on the
concept plan but would be barred from voting on any applications that
come in later. The two RFAs could go out as early as October with
approval of funding of applications one year from now.
In addition to the Burlingame meeting
site, members of the public can participate from two teleconference
locations in the Los Angeles area. The specific locations can be
found on the meeting agenda.
site, members of the public can participate from two teleconference
locations in the Los Angeles area. The specific locations can be
found on the meeting agenda.
The California Stem Cell Report will
provide live coverage of the entire meeting, filing reports as
warranted based on the Internet audiocast.
provide live coverage of the entire meeting, filing reports as
warranted based on the Internet audiocast.
Here are excerpts from CIRM's staff
document on the plan.
document on the plan.
“To accelerate therapeutic
development and delivery of stem cell therapies, CIRM proposes
establishing the CIRM Alpha Stem Cell Clinics Network (CASC Network).
The network will be designed to support projects emanating from
CIRM’s funding pipeline, as well as scientifically outstanding stem
cell products being developed worldwide and brought to California.
Conceptually, the CASC Network is intended to be a sustainable
infrastructure designed to support academic- and industry-initiated
clinical trials, and delivery of therapies proven safe and
effective.”“The major thrusts (of the overall
plan) will be:
• Development of clinical capacity
and associated resources designed to support the effective
implementation and execution of clinical trials and delivery of
registered stem cell therapies
• Compilation of data and
information concerning clinical trial experience and therapy outcomes
to further inform the research, regulatory, and general community
about the status of investigational stem cell interventions and
long-term outcomes
• Dissemination of information to
the public and counseling of patients and potential trial subjects
about therapeutic options and clinical trials involving stem cells in
the network and elsewhere.”
“The long-term vision is for the
Alpha Clinics to expand and accommodate a broad array of stem
cell-based clinical trials, where the trial meets the scientific,
clinical trial design and ethical standards set forth by the Alpha
Clinics Network, as well as FDA approved treatments.”The coordinating and information center
would be expected to :
“Build relationships with
Accountable Care Organizations, and participate in initiatives for
informing coverage and payment decisions
“Design strategies to attract
investors and philanthropists to CASC network
“Create business plans, and marketing
and branding strategies for financial sustainability of the Alpha
Clinics Sites and (the coordination/information center)”.
Source:Stem Cell Therapy
Comments Off on California’s $70 Million ‘Alpha’ Stem Cell Clinic Plan Headed for Approval Next Week |
July 21st, 2013
Emilie Russler and David Germain – New York Times
By Dr. Matthew Watson
Emilie Russler and David Germain New York Times Next month, the bride, who is studying for a Ph.D. in immunology, is to begin her second year and the groom, studying for a doctorate in molecular genetics and genomics, his fifth. The bride's mother retired as the director and the deputy to the ... |
Uncategorized
Comments Off on Emilie Russler and David Germain – New York Times |
July 21st, 2013
Indian Hill Music School donating sets and props for Newtown production – Boston Globe
By Dr. Matthew Watson
 Boston Globe | Indian Hill Music School donating sets and props for Newtown production Boston Globe Wayland resident Lindsay Farrer (inset bottom) is a medical geneticist at the Boston University Schools of Medicine and Public Health, where he is a professor, chief of biomedical genetics, and director of the Molecular Genetics Core Facility. He ... |
Uncategorized
Comments Off on Indian Hill Music School donating sets and props for Newtown production – Boston Globe |
July 21st, 2013
Enhanced prostate cancer gene transfer and therapy using a novel serotype chimera cancer terminator virus (Ad.5/3?CTV)
By Dr. Matthew Watson
Abstract
Few options are available for treating patients with advanced prostate cancer (PC). As PC is a slow growing disease and accessible by ultrasound, gene therapy could provide a viable option for this neoplasm. Conditionally replication?competent adenoviruses (CRCAs) represent potentially useful reagents for treating prostate cancer (PC). We previously constructed a CRCA, Cancer Terminator Virus (CTV), which showed efficacy both in vitro and in vivo for PC. The CTV was generated on a serotype 5?background (Ad.5?CTV) with infectivity depending on Coxsackie?Adenovirus Receptors (CARs). CARs are frequently reduced in many tumor types, including PCs thereby limiting effective Ad?mediated therapy. Using serotype chimerism, a novel CTV (Ad.5/3?CTV) was created by replacing the ...
MedWorm Sponsor Message: Find the best Christmas presents and January Sales in the UK with this simple shopping directory.
Uncategorized
Comments Off on Enhanced prostate cancer gene transfer and therapy using a novel serotype chimera cancer terminator virus (Ad.5/3?CTV) |
July 20th, 2013